Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies

Leukemia

Volumn 14, Issue 2, 2000, Pages 232-237

  Woo, M H ^a   Shuster, J J ^b   Chen, C ^a   Bash, R O ^c   Behm, F G ^a,d   Camitta, B ^e   Felix, C A ^f   Kamen, B A ^g   Pui, C H ^a,d   Raimondi, S C ^a,d   Winick, N J ^g   Amylon, M D ^h   Relling, M V ^a,i  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b University of Florida   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute myeloid leukemia; Epipodophyllotoxins; Glutathione S transferase genotype; GSTM1; GSTT1

Indexed keywords

ANTINEOPLASTIC AGENT; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; TENIPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FEMALE; GENDER; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0033954510     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401660     Document Type: Article

References (51)

1. Pui C-H, Ribeiro R, Hancock ML, Rivera GK, Evans WE, Raimondi S, Head DR, Behm FG, Mahmoud MH, Sandlund JT, Crist WM. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. New Engl J Med 1991; 325: 1682-1687.
2. Pui C-H, Relling MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE, Santana VM, Ribeiro RC, Sandlund JT, Mahmoud HH, Evans WE, Crist WM, Krance RA. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995; 9: 1990-1996.
3. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1995; 23: 86-98.
4. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 233-255.
5. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, Spect L, terlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-1986.
6. Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992; 3: 107-111.
7. Sugita K, Furukawa T, Tsuchida M, Okawa Y, Nakazawa S, Akatsuka J, Ohira M, Nishimura K. High frequency of etoposide-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 1993; 15: 99-104.
8. Pui C-H, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, Krance RA, Mahmoud HH, Ribeiro RC, Sandlund JT, Head DR, Evans WE, Crist WM, Rivera GK. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9: 1580-1684.
9. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999; 13: 335-342.
10. Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J Jr, Kalwinsky DK, Dahl GV, Murphy SB, Crist WM, Williams DL. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. New Engl J Med 1989; 321: 136-142.
11. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanan GR. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993; 11: 209-217.
12. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui CH. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12: 346-352.
13. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95: 13176-13181.
14. Relling MV, Evans R, Desiderio D, Dass C, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 1992; 261: 491-496.
15. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45: 352-358.
16. van Maanen JMS, DeVries J, Pappie D, van den Akker M, Lafleur VM, Retél J, van der Greef J, Pinedo HM. Cytochrome P450-mediated O-demethylation: a route in the metabolic activation of etoposide. Cancer Res 1987; 47: 4658-4662.
17. Mans DRA, Retel J, van Maanen JMS, Lafleur MVM, van Schaik MA, Pinedo HM, Lankelma J. Role of the semi-quinone free radical of the anti-tumour agent etoposide in the inactivation of single-and double-stranded φX174 DNA. Br J Cancer 1990; 62: 54-60.
18. Gantchev TG, Hunting DJ. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol 1998; 53: 422-428.
19. Gantchev TG, Hunting DJ. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16). Biochem Biophys Res Commun 1997; 237: 24-27.
20. Katki AG, Kalyanaraman B, Sinha BK. Interactions of the antitumor drug, etoposide, with reduced thiols in vitro and in vivo. Chem Biol Interact 1987; 62: 237-247.
21. van Maanen JM, de Ruiter C, Kootstra PR, Lafleur MV, de Vries J, Retel J, Pinedo HM. Inactivation of phi X174 DNA by the orthoquinone derivative or its reduction product of the antitumor agent VP 16-213. Eur J Cancer Clin Oncol 1985; 21: 1215-1218.
22. Mooney LA, Bell DA, Santella RM, Van Bennekum AM, Ottman R, Paik M, Blaner WS, Lucier GW, Covey L, Young TL, Cooper TB, Glassman AH, Perara FP. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 1997; 18: 503-509.
23. Anttila S, Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Nurminen T, Vainio H. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. Carcinogenesis 1994; 15: 1133-1135.
24. Hirvonen A. Combinations of susceptible genotypes and individual responses to toxicants. Environ Health Perspect 1997; 105 (Suppl. 4): 755-758.
25. Lafluente A, Pujol F, Carretero P, Villa JP, Cuchi A. Human glutathione S-transferase mu (GSTmu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 1993; 68: 49-54.
26. Nazar-Steward V, Motulsky AG, Eaton DL, White E, Hornung SK, Leng ZT, Stapleton P, Weiss NS. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 1993; 53: 2313-2318.
27. Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 1994; 15: 415-418.
28. Fryer AA, Zhao L, Aldersea J, Bogglid MD, Perrett CW, Clayton RN, Jones PW. The glutathione S-transferase: polymerase chain reaction studies on the frequency of the GSTM1 null genotype in patients with pituitary adenomas. Carcinogenesis 1993; 14: 563-566.
29. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53: 2994-2999.
30. Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996; 347: 295-297.
31. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abromowitch M, Mirro J, Ochs J, Look AT, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
32. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl J Med 1998; 338: 499-505.
33. Felix CA, Hosler MR, Winick NJ, Masterson M, Wilson AE, Lange BJ. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 1995; 85: 3250-3256.
34. Chen C-L, Liu Q, Pui C-H, Rivera GK, Sandlund JT, Ribeiro R, Evans WE, Relling MV. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997; 89: 1701-1707.
35. Chen C-L, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks Pharmacogenetics 1996; 6: 187-191.
36. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
37. Camitta BM, Pullen J, Murphy S. Biology and treatment of acute lymphocytic leukemia in children. Semin Oncol 1997; 24: 83-91.
38. Pui CH, Evans WE. Acute lymphoblastic leukemia. New Engl J Med 1998; 339: 605-615.
39. Rivera GK, Pui C-H, Santana VM, Hancock ML, Mahmoud H, Sandlund JT, Ribeiro RC, Furman W, Marina N, Crist WM. Progress in the treatment of adolescents with acute lymphoblastic leukemia. Cancer 1993; 71: 3400-3405.
40. Raimondi SC, Behm FG, Roberson PK, Williams DL, Pui C-H, Crist WM, Look AT, Rivera GK. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 1990; 8: 1380-1388.
41. Brockmoller J, Gross D, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class μ isoenzymes μ and GSTM1 a in lung cancer patients and controls. Cancer Res 1993: 53: 1004-1011.
42. Brockmoller J, Kerb J, Drakoulis N, Staggeldt B, Roots I. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res 1993; 54: 4103-4111.
43. Heagerty AH, Fitzgerald D, Smith A, Bowers B, Jones P, Fryer AA, Zhao L, Alldersea J, Strange RC. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumors. Lancet 1994; 34: 3266-3268.
44. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994; 15: 1077-1081.
45. Winick N, Buchanan GR, Kamen BA. Secondary acute myeloid leukemia in Hispanic children. J Clin Oncol 1993; 11: 1433.
46. Sanchez MA. Ethnic differences in risk and prognosis factors for breast cancer (letter). Cancer 1996; 77: 593-594.
47. Villalona-Calero MA. Secondary acute myelogenous leukemia in children with Latin-American ancestry. J Clin Oncol 1993; 11: 2286.
48. Hoyo-Vadillo C, Castaneda-Hernandez G, Herrera JE, Vidal-Garate J, Moreno-Ramos A, Chavez F, Hong E. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. J Clin Pharmacol 1989; 29: 816-820.
49. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. Human glutathione S-transferase Theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994: 300: 271-276.
50. Warwick A, Sarhanis P, Redman C, Pemble S, Taylor JB, Ketterer B, Jones P, Alldersea J, Gilford J, Yengi L, Fryer A, Strange RC. Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: interactions with GSTM1, CYP2D6 and smoking. Carcinogenesis 1994; 15: 2841-2845.
51. Warholm M, Alexandrie AK, Hogberg J, Sigvardsson K, Rannug A. Polymorphic distribution of glutathione transferase activity with methyl chloride in human blood. Pharmacogenetics 1994; 4: 307-311.